Costs of dyslipidemia

References

• American Heart Association, Anonymous, 2002 Heart and Stroke Statistical Update. American Heart Association, TX, USA (2002)
   Google Scholar
• Pedersen TR, Kjekshus J, Berg K. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
   Google Scholar
• Shepherd J, Cobbe SM, Ford I etal Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng. I Med. 333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA eta]. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. I Med. 335, 1001–1009 (1996).
   Google Scholar
• Lipid Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl. Merl 339, 1349–1357 (1998).
   Google Scholar
• Downs JR, Clearfield M, Weis S et at. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JANA 279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Baden WE, High-density lipoprotein cholesterol as an independent risk-factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am Catrliol 86(Suppl), L19—L22 (2000).
   Google Scholar
• Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Diabetes Atherosclerosis Intervention Study Investigators. Lancet 357, 905–910 (2001).
   Google Scholar
• Expert panel on detection, evaluation,and treatment of high blood cholesterol in adults. Third Report of the Expert Panel on Detection, Evaluation and Treatment of Ifigh Blood Cholesterol in Adults (Adult Treatment Panel III). Full Report. National Cholesterol Eduction Program (2001).
   Google Scholar
• •Highlights the effectiveness and cost-effectiveness of lipid-lowering therapies and their public health implications.
   Google Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JA/V/A 282, 2340–2346 (1999).
   Google Scholar
• Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JA MA 251, 351–364 (1984).
   Google Scholar
• Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAIVIA 251, 365–374 (1984).
   Google Scholar
• Brown BG, Zhao X-Q, Chait A etal. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl. J. Med 345, 1583–1592 (2001).
   Google Scholar
• Committee of Principal Investigators, A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Brit. Heart 40, 1069–1118 (1978).
   Google Scholar
• Frick MH, Elo 0, Haapa K et al Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl.J. Med. 317, 1237–1245 (1987).
   Google Scholar
• Rubins FIB, Robins SJ, Collins D eta]. Gemfibrozil for the secondary prevention of coronary heart disease in men with low Levels of high-density lipoprotein cholesterol. N Engl. J. Med 341, 410–418 (1999).
   Google Scholar
• Sueta CA, Chowdhury M, Boccuzzi SJ etal Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am. J. Camliol 83, 1303–1307 (1999).
   PubMed Web of Science ®Google Scholar
• NDC Health. PharmaTrendssm 2001 Year in Review. NDC Health, (2002).
   Google Scholar
• Whincup PH, Emberson JR, Lennon L et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 88, 25–29 (2002).
   PubMed Web of Science ®Google Scholar
• IMS World Review 2002. Pointe-Claire, Quebec, Canada (2002).
   Google Scholar
• The National Institute for Healthcare Management, Research and Educational Foundation. Anonymous. Prescription drug expenditures in 2001: another year of escalating costs. NIHCM Foundation, Washington DC, USA (2002).
   Google Scholar
• Prosser LA, Stinnett AA, Goldman PA etal Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann. Intern. Med 132, 769–779 (2000).
   PubMed Web of Science ®Google Scholar
• Tsevat J, Kuntz KM, Orav EJ eta]. Cost- effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heartj 141, 727–734 (2001).
   Google Scholar
• Johannesson M, Jönsson B, Kjekshus J for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. NE,Lj Med 336, 332–336 (1997).
   Google Scholar
• Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch. Intern. Med. 159, 593–600 (1999).
   Google Scholar
• Grover SA, Coupal L, Zowall H et al How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 24, 45–50 (2001).
   PubMed Web of Science ®Google Scholar
• Stinnett AA, Mittleman MA, Weinstein MC et al. Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russel LB, Weinstein V. (Eds) . Oxford University Press, NY, USA (1996).
   Google Scholar
• Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy in older patients with myocardial infarction. Ann. Intern. Med. 132, 780–787 (2000).
   Google Scholar
• Pedersen TR, Kjekshus J, Berg K et al Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 93, 1796–1802 (1996).
   Google Scholar
• Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary versus secondary prevention. Arch. Intern. Med. 158, 655–662 (1998).
   Google Scholar
• Manninen V, Elo 0, Frick H et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260, 641–651 (1988).
   Google Scholar
• Buchwald H, Varco RL, Math JP and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl. J. Med 323, 946–955 (1990).
   Google Scholar
• SHEP Co-operative Research Group. Prevention of stroke antihypertensive drug treatment in older persons with isolated systolic hypertension. JAIVIA 265, 255–264 (1991).
   Google Scholar
• Wikstrand J, Warnold I, Olsson G etal Primary prevention with metoprolol in patients with hypertension. JAMA 259, 1976–1982 (1988).
   PubMed Web of Science ®Google Scholar
• The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multipile Risk Factor Intervention Trial: findings related to a priori hypothesis of the trial. JA/V/4 263, 1795–1801 (1990).
   Google Scholar
• Grover SA, Coupal L, Zowall H, Dorais M Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 102, 722–727 (2000).
   Google Scholar
• Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J. Cardiopulmonary Rehabil 20, 147–155 (2000).
   PubMedGoogle Scholar
• Ramsay LE, Haq TU, Jackson PR et al Targeting lipid-lowering drug therapy for primary prevention of coronary heart disease: an updated Sheffield table. Lancet 348, 387–388 (1996).
   PubMed Web of Science ®Google Scholar
• Ramsay LE, Haq IU, Jackson PR, Yeo WW. The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet 348, 1251–1252 (1996).
   PubMedGoogle Scholar
• Wood D, De Backer G, Faergeman 0 eta]. Prevention of coronary heart disease in clinical practice: summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention (Task Force Report). Atherosclerosis 140, 199–270 (1998).
   Google Scholar
• Pickin DM, McCabe CJ, Ramsay LE eta]. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 82, 325–332 (1999).
   Google Scholar
• •• Highlights the effectiveness and cost-effectiveness of lipid-lowering therapies and their public health implications.
   Google Scholar
• Fedder DO, Koro CE, LItalien GJ. New National Cholesterol Education Program III Guidelines for primary prevention lipid-lowering drug therapy: project impact on the size, sex and age distribution of the treatment-eligible population. Circulation 105, 152–156 (2002).
   PubMed Web of Science ®Google Scholar
• Goldman L, Coxson P, Hunink MGM etal The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II Guidelines. jAm Coll Carcliol 34, 768–776 (1999).
   PubMed Web of Science ®Google Scholar